Abiomed, Inc. (ABMD)’in fiyatı nedir?

Abiomed, Inc. (ABMD)’in fiyatı $381.02’dir

Abiomed, Inc. (ABMD)’in piyasa değeri nedir?

Abiomed, Inc. (ABMD)’in piyasa değeri $17.18B’dir.

Abiomed, Inc. (ABMD) Fiyat Geçmişi

Abiomed, Inc. specializes in the creation and distribution of advanced medical technology designed to support or substitute the heart's pumping action in patients suffering from heart failure, while also offering ongoing care for these individuals. Its product portfolio includes various devices from the Impella family. The Impella 2.5 is a tiny percutaneous heart pump featuring an integrated motor and sensors, alongside the Impella CP, which is utilized by interventional cardiologists in catheterization labs and by cardiac surgeons during operations. Other Impella models such as the 5.0, LD, and 5.5 are also percutaneous micro heart pumps, primarily employed in surgical settings. The Impella RP is a percutaneous catheter-based axial flow pump. Beyond the pumps, Abiomed offers the Impella SmartAssist platform, which leverages optical sensors for precise pump placement and uses algorithms to enhance native heart function assessment during patient weaning. Its Impella Connect system provides secure, cloud-based remote monitoring of the automated Impella controller for medical staff. The company also markets the OXY-1 System, a portable device for external respiratory support. Furthermore, Abiomed is actively developing several innovations, including the Impella ECP pump for high blood flow rates, the Impella XR Sheath for smaller access during Impella procedures, the Impella BTR percutaneous micro heart pump, and preCARDIA, a catheter-based superior vena cava therapy system aimed at quickly addressing acute decompensated heart failure. Abiomed distributes its products globally through its dedicated direct sales and clinical support teams, reaching regions such as the United States, Japan, Canada, countries across Europe (including Germany and France), Latin America, the Asia-Pacific, and the Middle East. Founded in 1981 and headquartered in Danvers, Massachusetts, Abiomed, Inc. has been operating as a subsidiary of Johnson & Johnson since December 22, 2022.

Yıl	Performans
2022	16.10%
2021	14.41%
2020	60.46%
2019	-43.20%
2018	64.57%
2017	66.53%
2016	33.37%
2015	132.04%
2014	36.12%
2013	104.83%
2012	-31.56%
2011	96.23%
2010	14.02%
2009	-44.56%
2008	6.85%
2007	9.08%
2006	46.56%
2005	-35.99%
2004	91.48%
2003	75.82%
2002	-75.54%
2001	-27.10%
2000	18.11%
1999	318.77%
1998	-42.18%
1997	31.66%
1996	1.04%
1995	137.38%
1994	-33.27%
1993	-33.79%
1992	-28.45%
1991	178.66%
1990	-48.82%
1989	28.81%
1988	65.32%
1987	0.00%

Yıl

Performans

2022

16.10%

2021

14.41%

2020

60.46%

2019

-43.20%

2018

64.57%

2017

66.53%

2016

33.37%

2015

132.04%

2014

36.12%

2013

104.83%

2012

-31.56%

2011

96.23%

2010

14.02%

2009

-44.56%

2008

6.85%

2007

9.08%

2006

46.56%

2005

-35.99%

2004

91.48%

2003

75.82%

2002

-75.54%

2001

-27.10%

2000

18.11%

1999

318.77%

1998

-42.18%

1997

31.66%

1996

1.04%

1995

137.38%

1994

-33.27%

1993

-33.79%

1992

-28.45%

1991

178.66%

1990

-48.82%

1989

28.81%

1988

65.32%

1987

0.00%

Şirket	Hisse fiyatı	Değişim 1yıl%	Ülke
Abbott Laboratories ABT.US	$116.66	-11.53%	US
Stryker Corporation SYK.US	$328.27	-16.02%	US
Medtronic plc MDT.US	$92.91	0.95%	IE
Boston Scientific Corporation BSX.US	$48.98	-53.41%	US
Siemens Healthineers AG SHL.DE	$47.58	-13.88%	DE

Şirket

Hisse fiyatı

Değişim 1yıl%

Ülke